Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wei Zhao has a total of 375 co-authors. Here are the top co-authors by number of shared publications:

  • Bao Zhang

    BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, Ministry of Education Key Laboratory of Infectious Diseases Research in South China, School of Public Health, Southern Medical University, Guangzhou, China

    26 shared publications
  • Chenguang Shen

    BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, Ministry of Education Key Laboratory of Infectious Diseases Research in South China, School of Public Health, Southern Medical University, Guangzhou, China

    21 shared publications
  • Jianhai Yu

    BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, Key Laboratory of Infectious Diseases Research in South China, School of Public Health, Southern Medical University, No. 1023, South Shatai Road, Baiyun District, Guangzhou, 510515, Guangdong Province, China

    17 shared publications
  • Li Zhu

    BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, Key Laboratory of Infectious Diseases Research in South China, School of Public Health, Southern Medical University, No. 1023, South Shatai Road, Baiyun District, Guangzhou, 510515, Guangdong Province, China

    16 shared publications
  • Bao Zhang

    BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, Key Laboratory of Infectious Diseases Research in South China, School of Public Health, Southern Medical University, No. 1023, South Shatai Road, Baiyun District, Guangzhou, 510515, Guangdong Province, China

    15 shared publications
  • Qinghua Wu

    BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, Key Laboratory of Infectious Diseases Research in South China, School of Public Health, Southern Medical University, No. 1023, South Shatai Road, Baiyun District, Guangzhou, 510515, Guangdong Province, China

    14 shared publications

Latest Publications

  • Open Access

    Paper-Based Biosensors for Monitoring Binding, Blocking, and Surrogate Neutralizing Antibody Responses Against Viral Infections

    by Yiren Yin, Yujie Yi, Yazheng Yu, Tatyana Aleksandrovna Khrustaleva, Linlin Zhai, Jianhai Yu, Wei Zhao, Chenguang Shen

    Virus-specific antibody responses, including binding antibodies and neutralizing antibodies (nAbs), are important indicators of antiviral immune status after infection or immunization. They provide complementary information on antiviral humoral immunity after infection or vaccination. Antigen-binding antibodies indicate previous exposure and the magnitude of the immune response, whereas receptor-blocking and functional neutralization assays assess whether antibodies interfere with viral entry or infection. Conventional neutralization assays, such as plaque reduction neutralization tests and pseudovirus neutralization tests, provide functional information but are labor-intensive, time-consuming, biosafety-restricted, and difficult to deploy for large-scale or decentralized monitoring. Paper-based biosensors, including lateral flow assays (LFAs), microfluidic paper-based analytical devices (μPADs), and paper-based ELISA, have emerged as promising point-of-care tools owing to their low cost, portability, simple operation, and compatibility with visual or digital readouts. This review critically evaluates these platforms according to whether they measure antigen-binding antibodies, receptor-blocking activity, surrogate neutralization, or functional neutralization and summarizes the applications of these three platforms for monitoring antibody responses against SARS-CoV-2, influenza, dengue, Zika, and monkeypox viruses. Unlike previous reviews that mainly focus on general paper-based biosensor design or conventional nAb assays, this review emphasizes the distinction between antigen-binding, receptor-blocking, and surrogate neutralization readouts, and critically discusses how paper-based signals should be interpreted in relation to functional immunity. We further analyze key translational challenges, including quantitative accuracy, antigen cross-reactivity, standardization, clinical validation, regulatory positioning, and real-world implementation. Future development should combine multiplex detection, standardized calibration, digital and AI-assisted interpretation, and clinically validated assay formats. Paper-based biosensors have considerable potential for decentralized antibody monitoring and public health surveillance, but their clinical utility depends on clear assay positioning and validation against appropriate functional or reference methods.

  • Open Access

    From clinical fluids to environmental matrices: quantitative monitoring of infectious monkeypox virus based on PMA-qPCR during the Guangdong outbreak

    by Jianhai Yu, Xin Zhang, Xiaoting Xie, Yutian Miao, Shen Huang, Li Zhu, Yan Zhan, Yifan Lin, Changyun Sun, Linqing Wang, et al.

    Background: Mpox, caused by monkeypox virus (MPXV), remains a public health priority. Standard qPCR detects viral DNA but cannot distinguish infectious virions from residual genetic material of inactivated virus, complicating transmission risk assessment. This study aimed to develop a rapid assay for quantifying infectious MPXV across clinical and environmental matrices in Guangdong Province, China. Methods: We developed a propidium monoazide-assisted qPCR (PMA-qPCR) assay that selectively amplifies DNA from intact virions, and embedded it within the Guangdong provincial Center for Disease Control and Prevention surveillance network. We examined 23 clinical fluid specimens from 15 mpox patients, 337 surface swabs and 53 domestic wastewater samples from patient living environments, and 498 terminal wastewater samples from flights and sewage treatment plants collected between June 2023 and August 2024. Decay kinetics were evaluated at 25 °C and 30 °C under varying pH, with initial viral loads of 10 3 and 10 4 PFU/mL. Results: PMA-qPCR discriminated infectious from non-infectious virus. Co-incubation with 50 μM PMA and 0.005% SDS effectively blocked amplification of non-infectious DNA, and the assay showed quantitative concordance with the standard plaque assay. Infectious MPXV loads were highest in skin lesions and anal swabs, exceeding throat swabs by more than 100-fold. Among surface samples, 41.54% (140/337) tested positive for MPXV DNA by qPCR, but only 25.71% (36/140) of these contained infectious virus at low loads (126.79 ± 93.57 PFU/mL). For wastewater, 11.32% (6/53) of domestic samples from patient living environments tested positive by qPCR, yet no infectious MPXV was detected. No MPXV DNA was detected in 498 terminal wastewater samples from flights or sewage treatment plants. Decay experiments demonstrated that when the initial concentration was 10 3 to 10 4 PFU/mL, infectious MPXV decreased by more than 99% within 48 h, with accelerated decay under acidic pH and elevated temperature, particularly at lower initial concentrations. Conclusions: PMA-qPCR provides a practical tool for rapid cross-matrix quantification of infectious MPXV. Direct contact with skin lesions or anal secretions likely dominates transmission, whereas environmental persistence is limited. Testing for infectious virus within 48 h of collection is recommended, as infectious MPXV decays by over 99% within this window.

  • Open Access

    Stage-of-Action Characterization of a Non-Sulfated Heteropolysaccharide from Gracilaria lemaneiformis Against Dengue Virus Serotype 2

    by Jiaxin Dai, Yingfang Liu, Jingshu Li, Zihan He, Kexin Xi, Yushan Jiang, Xuenan Zhang, Kefeng Wu, Bao Zhang, Wei Zhao, et al.

    Marine algal polysaccharides have been widely investigated as antiviral candidates, yet nearly all anti-dengue studies have focused on sulfated species. Whether algal polysaccharides lacking prominent sulfation can inhibit dengue virus (DENV) remains unexplored. Here, we profiled the stage-specific antiviral activity of a heteropolysaccharide (GLHP) from Gracilaria lemaneiformis, whose Fourier-transform infrared (FT-IR) spectrum lacks characteristic sulfate ester absorption bands, against DENV serotype 2 (DENV-2) in Huh7 and BHK-21 cells. GLHP exhibited low cytotoxicity (CC50 exceeding 1000 μg/mL in Huh7 cells and approximately 950 μg/mL in BHK-21 cells). Time-of-addition analysis revealed that co-inoculation GLHP treatment (Co-inoc.) produced the strongest and most consistent inhibition of intracellular viral RNA, whereas pre-inoculation GLHP treatment (Pre-inoc.) was ineffective, indicating that the antiviral activity is predominantly associated with the virus–cell contact and entry stage. GLHP additionally reduced extracellular progeny virus output under post-inoculation GLHP treatment (Post-inoc.) conditions, and this reduction exceeded the corresponding change in intracellular viral RNA levels, suggesting an additional effect that may involve either a late replication step or secondary entry blockade of progeny virions. Attenuation of virus-induced cytopathic effects under Co-inoc. conditions further supported the antiviral activity. To our knowledge, these findings identify GLHP as the first non-sulfated marine polysaccharide shown to exhibit stage-defined antiviral activity against DENV-2 and support further investigation of its antiviral potential and structural determinants.

  • Open Access

    Bioinformatics identification of copyback and multihost-adapted defective viral genomes in dengue virus

    by Jianhai Yu, Hao Wu, Yan Zhan, Yuan Liang, Linlin Xiang, Xuling Liu, Xiaoting Xie, Li Zhu, Qinghua Wu, Weiwei Xiao, et al.

    Introduction: Defective viral genomes (DVGs) have been detected in clinical samples, and their antiviral effects have been verified. However, due to the limitations of traditional methods, all the reported DENV DVGs to date are Deletion DVGs, and it has not been proven that these DVGs can be stabilized across different hosts. Methods: We used the bioinformatics software DVGfinder with various dengue virus NGS data, including samples from patients, Aedes albopictus , C6/36 cells, and Vero cells, to identify DVGs. We compared the distribution of DVGs across different hosts and analyzed the dynamics of DENV-1 DVGs during serial passaging, identifying DVGs that are stably maintained across hosts. Results: First of all, we found copyback type DVGs in different datasets, with the dominant DVGs in patient sera being 3’ copyback. Secondly, we observed that in C6/36 cells and Aedes albopictus , the DVGs did not change significantly with DENV-1 passages, while in Vero cells, the number of specific Deletion DVGs continuously increased with DENV-1 passage. Finally, using clustering algorithms, we identified a set of candidate deletion DVGs predicted to stably exist across different hosts. One of these candidates, designated DeletionA6 (BP 1320, RI 7700), was experimentally validated by nested PCR in sera from patients infected with DENV-1 to DENV-4. Discussion: This study describes the distribution patterns of DVGs across different samples and provides preliminary bioinformatic evidence for a subset of deletion DVGs.

  • Open Access

    Dual role of Japanese encephalitis virus fusion loop peptide antibodies in Zika virus infection

    by Kexin Xi, Xuenan Zhang, Jingshu Li, Yuqi Zhao, Xiaoting Xie, Chenguang Shen, Bao Zhang, Li Zhu, Weiwei Xiao, Chengsong Wan, et al.

    Zika virus (ZIKV) is a key member of the Flavivirus genus that has emerged as a major global public health concern. The fusion loop region (residues 98–110), located within domain II of the envelope protein, is highly conserved among flaviviruses, including ZIKV and Japanese encephalitis virus (JEV). However, the functional consequences of such conservation for cross-reactive immunity remains unclear. Here, we integrated bioinformatic analyses, functional assays in vitro and mouse models in vivo to systematically determine the effects of antibodies directed against the JEV fusion loop (FL) region on ZIKV infection. Sequence alignment and structural analysis revealed complete amino acid identity and almost identical three-dimensional conformations between the FL regions of the two viruses, providing a molecular basis for cross-reactivity. Antisera generated against the JEV FL region recognized ZIKV particles and displayed concentration-dependent bidirectional effects. Increased and decreased antibody levels respectively neutralized viral entry and replication, and facilitated infection via antibody-dependent enhancement (ADE). These effects were confirmed in vivo , in which high and low antibody doses reduced tissue pathology and improved survival, and increased viremia and exacerbated inflammatory responses, respectively. These findings highlight the importance of antibody concentration in determining whether cross-reactive responses to conserved structural elements engender neutralization or enhancement response. Our findings provide experimental evidence for assessing ZIKV susceptibility in JEV-vaccinated populations and offer structural insights for designing flavivirus vaccines that maximize protection while minimizing ADE risk. These findings further highlight potential pathogenic and clinical considerations for optimizing vaccine formulations to reduce cross-reactive enhancement risks.

  • Open Access

    Structural Insights into the Impact of the M142I Mutation in Monkeypox Virus G9 Protein on Subcomplex Formation Revealed by AlphaFold 3 Modeling

    by Xudong She, Yuan Liang, Linqing Wang, Yifan Lin, Xuenan Zhang, Li Zhu, Qinghua Wu, Weiwei Xiao, Chengsong Wan, Kexin Xi, et al.

    The membrane fusion process, mediated by the entry fusion complex (EFC) of the monkeypox virus (MPXV), is crucial for host cell invasion. Apolipoprotein B mRNA Editing Catalytic Polypeptide-like 3 (APOBEC3)-driven mutation bias is a key factor in MPXV’s adaptive evolution during its global spread. However, how these mutations affect the structure and function of EFC proteins remains poorly understood. To address this, we performed genomic mutation analysis on globally circulating MPXV clades Ib and IIb, combined with protein monomer, binary, and quaternary complex structure modeling based on AlphaFold 3 and experimental validation by ELISA. We first delineated the mutational spectra of all 11 EFC proteins, revealing that although EFC proteins in clade Ib are highly conserved, lineage IIb B exhibits extensive APOBEC3-driven mutations and the G9 M142I mutation is identified as a lineage-associated APOBEC3-type mutation of lineage IIb B. Structural predictions revealed that while the M142I mutation does not alter G9 monomer folding, it induces a conformational shift in the G9/A16 subcomplex. Furthermore, within the predicted G9/A16/A56/K2 quaternary complex, this mutation enlarges the interfacial gap and reduces docking stability between the G9/A16 subcomplex and A56/K2. Experimental validation demonstrated that the M142I mutation significantly reduces the binding affinity of G9 for A16 and impairs the recruitment of A56/K2 to the quaternary complex, confirming the computationally predicted mechanism of interface destabilization. These findings highlight a dynamic interplay between APOBEC3-driven evolution and EFC protein structure, demonstrating that the M142I mutation alters EFC complex assembly dynamics and may shift the regulatory balance of the membrane fusion system. These structural changes provide molecular insights into MPXV lineage differentiation, though direct functional assays are required to determine the net effect on viral entry efficiency.

  • Open Access

    Characteristics and Screening Strategies of Hepatitis B in Guangdong Province, China

    by Weizhao Lin, Xiaoping Shao, Junjie Wang, Hongqing Wen, Jiahong Liu, Can Xiong, Zixia Qian, Wei Zhao, Jun Liu, Jiufeng Sun

    Determining the characteristics of hepatitis B virus (HBV) infection in the healthy population and evaluating the effectiveness of detection strategies will facilitate the optimization of hepatitis B screening strategies in the community and accelerate the elimination of HBV infection in China by the end of 2030. Hepatitis B surface antigen (HBsAg)-electrochemiluminescence immunoassays (ECLIAs), HBsAg-rapid diagnostic tests (RDTs), and HBV DNA-nucleic acid tests (NATs) were performed on serum samples from 2721 community-based healthy participants in Guangdong Province. The screening performance of the RDT and NAT and the distribution characteristics of HBsAg and HBV DNA were evaluated. The prevalence rates of HBsAg-ECLIA, HBsAg-RDT and HBV DNA-NAT in Guangdong Province were 6.10% (95% CI: 5.26~7.06), 4.96% (95% CI: 4.21~5.84) and 6.55% (95% CI: 5.64~7.49), respectively, and the prevalence rates for the three methods for individuals aged over 30 years were 11.18%, 10.92% and 12.57%, respectively. When the ECLIA was used as the gold standard, the sensitivities of the RDT, NAT and RDT and NAT in parallel were 80.7% (95% CI: 73.9~86.4), 86.7% (95% CI: 80.6~91.5) and 93.4% (95% CI: 88.5~96.6), respectively, and the sensitivity of the RDT and NAT in parallel was greater than that of the RDT alone (p < 0.001). The parallel RDT and NAT revealed an additional cost–benefit ratio (ACBR) < 1 for males and individuals aged over 30 years, which indicated that switching from the RDT screening strategy to the RDT and NAT in parallel is more cost effective. Adults aged over 30 years are the main population with hepatitis B infection in Guangdong Province, China, whose prevalence of HBsAg-ECLIA was 11.18%. Single RDT screening is prone to miss individuals with low levels of HBsAg. It is recommended to implement an RDT and NAT in parallel for individuals older than 30 years.

  • Open Access

    Erratum for Li et al., “Bispecific antibodies targeting MPXV A29 and B6 demonstrate efficacy against MPXV infection”

    by Mengjun Li, Jiayin Chen, Fuxiang Wang, Jiahua Kuang, Yun Peng, Sadia Asghar, Wei Zhao, Yang Yang, Chenguang Shen

  • Open Access

    Development and characterization of neutralizing monoclonal antibodies against clinically relevant human adenovirus subgroup B serotypes

    by Yuelin Wang, Wei Dou, Yingying Chen, Ke Liu, Mengjun Li, Tyuji Hoshino, Yushan Jiang, Vladislav Victorovich Khrustalev, Alexey V. Churov, Alexander N. Orekhov, et al.

    Human adenoviruses (HAdVs), particularly subgroup B serotypes HAdV-3 and HAdV-55, are associated with severe respiratory disease and currently lack targeted therapies. While neutralizing monoclonal antibodies (nMAbs) offer promising therapeutic potential, the specific nMAbs targeting these serotypes remain poorly characterized. Therefore, this study aimed to generate and evaluate the efficacy of serotype-specific nMAbs against HAdV-3 and HAdV-55. Mice were immunized with HAdV-3 virions, HAdV-55 virions, or recombinant fiber knob proteins (HAdV-55/-7) for the generation of serotype-specific nMAbs, and their efficacy was systematically evaluated using in vitro assays and an in vivo tree shrew model. Through comprehensive screening, eleven MAbs were identified with specificity against HAdV-3 (six clones) or HAdV-55/-7 fiber knob (five clones). Four nMAbs exhibited potent neutralizing activity: 13F12 (half-maximal inhibitory concentration, IC50: 3.8 μg/mL), 8D2 (IC50: 15.1 μg/mL), 3A3 (IC50: 14.9 μg/mL) against HAdV-3 virions, and 8F2 with neutralizing efficacy against HAdV-55 virions (IC50: 30.4 μg/mL). Western blot analysis revealed that MAbs 13F12 and 8F2 targeted the fiber protein, whereas 8D2 and 3A3 bound to the hexon protein. Furthermore, in vivo evaluations demonstrated that 13F12 significantly reduced viral loads in nasal turbinates and attenuated lung pathology in HAdV-3-infected tree shrews. Mechanistically, all nMAbs inhibited infection by blocking viral attachment (P < 0.01 vs. controls). In conclusion, this study underscores the therapeutic potential of targeting viral entry and highlights 13F12 as a promising candidate for HAdV prophylaxis.